Benzylpiperazine

Benzylpiperazine
Clinical data
Routes of
administration
Oral, intravenous, insufflation
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
BioavailabilityUnknown
MetabolismHepatic
Elimination half-life5.5 Hours
ExcretionRenal
Identifiers
  • 1-Benzylpiperazine
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.018.567 Edit this at Wikidata
Chemical and physical data
FormulaC11H16N2
Molar mass176.258 g/mol
3D model (JSmol)
  • C1(CN2CCNCC2)=CC=CC=C1
  • InChI=1S/C11H16N2/c1-2-4-11(5-3-1)10-13-8-6-12-7-9-13/h1-5,12H,6-10H2 checkY
  • Key:IQXXEPZFOOTTBA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Benzylpiperazine, commonly referred to as BZP is an recreational drug. It is also available with trade names such as "A2", "Frenzy" and "Nemesis", It is a stimulant and may cause Euphoria. People believe it works in a way similar to MDMA. The effects produced by BZP are comparable to those produced by amphetamine. Side-effects include acute psychosis, problems with the kidneys Adverse effects have been reported following its use including acute psychosis and seizures. It does not appear to be very addictive and no deaths have been reported following taking BZP once. There have been at least two deaths which resulted from the combination of BZP and MDMA. Its sale is banned in a few countries, including the United States, Australia, New Zealand and in parts of Europe. However, its legal status is currently less restrictive in some other countries such as Ireland and Canada. The European Union is currently changing its laws to regulate this substance more.